TuHURA reports partial responses in 3 patients in IFx-2.0 MCC trial
Tweet Send to a Friend
TuHURA Biosciences, Inc. (NASDAQ: HURA) released initial data from the first three patients enrolled in its open-label Phase 1b/2a study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




